Abstract for presentation at 38th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine 2008

Amyloid Imaging with 18F-BAY94-9172 in the Differential Diagnosis of Dementia

  • Prof Christopher Rowe, Department of Nuclear Medicine, Centre for P.E.T., Austin Health, Melbourne, Australia
  • Dr Uwe Ackermann, Department of Nuclear Medicine, Centre for P.E.T., Austin Health, Melbourne, Australia
  • Dr Rachel Mulligan, Department of Nuclear Medicine, Centre for P.E.T., Austin Health, Melbourne, Australia
  • Dr Graeme O'Keefe, Department of Nuclear Medicine, Centre for P.E.T., Austin Health, Melbourne, Australia
  • Dr Thomas Dyrks, Bayer Schering Pharma, Berlin, Germany
  • Dr Ludger Dinkelborg, Bayer Schering Pharma, Berlin, Germany
  • Prof Colin Masters, The Mental Health Research Institute of Victoria, Australia
  • Dr Victor Villemagne, Department of Nuclear Medicine, Centre for P.E.T., Austin Health, Melbourne, Australia

    • Objectives : Clinical distinction between Alzheimer’s disease (AD) and Frontotemporal lobar degeneration (FTLD) is inaccurate. Beta-amyloid (Aβ) imaging with 11C-PiB PET can distinguish AD (extensive Aβ) from FTLD (no Aβ) but the short half-life of carbon-11 is
    problematic for clinical use. The purpose of this study was to compare patients with AD to patients with FTLD and age matched healthy controls (HC) using 18F-BAY94-9172, a novel 18F labelled, stilbene based, Aβ radioligand
    Methods : Fifteen HC, 5 FTLD and 15 AD patients with mild to moderate dementia, underwent PET imaging with 300 MBq 18F-BAY94-9172. Standardized Uptake Volume ratios (SUVR) were calculated using the cerebellum as reference region 90-120 min PI
    Results : All AD subjects showed extensive cortical binding. There was no cortical uptake in most FTLD or HC subjects. One FTLD (semantic dementia subtype) and three HC showed mild cortical binding but less than in AD. Higher SUVR in neocortical areas were observed in AD (2.02±0.28) when compared with HC (1.29±0.17) and FTLD (1.22±0.17)
    Conclusions : In contrast to AD, most FTLD subjects show no cortical 18F-BAY94-9172 binding consistent with both histopathological and 11C-PiB PET studies of Aβ in these conditions. 18F-BAY94-9172 PET should assist in the diagnosis of AD from FTLD. The robust visual findings, simplicity of the semiquantitative approach and the longer radioactive half-life are well suited to clinical use

    Conference Organiser - ICMS Pty Ltd